T-25: ClinLine.ru: The New Integrated Infomedia Russian Platform for all Parties Involved in Clinical Trials
Poster Presenter
Oksana Karavaeva
ClinOps Director
IPHARMA LLC Russian Federation
Objectives
To discuss the opportunities and purposes of ClinLine – the first Russian clinical trial platform for Patients, Investigators, Sponsors and CRO, which could facilitate clinical trial search, site selection, patient recruitment, and improve transparency of clinical trial process in Russia
Method
The database for clinical trials, investigators and clinical sites was developed based on official MoH registers. The platform objectives are: to encourage patients in drug development, streamline communication between patients and investigators, improve site selection, feasibility, pre-screening
Results
The platform was launched in July 2018. The functionality includes cross-searching of clinical trials, sites and investigators, registration and creating profiles of patients/healthy volunteers, investigators and sponsors/CRO, authorization of investigators with access to patient registry, application/invitation to a clinical trial, chat between patients/healthy volunteers and investigators, chat between investigators and sponsors/CRO, rating of patients/healthy volunteers and investigators, access to investigators profiles for sponsors/CRO, real-time analytics of the clinical trials market for sponsors/CRO. The database is up-to-date and synchronized daily; it contains 6,204 trials including 1,712 ongoing studies, 3,947 investigators, and 1,467 accredited clinical sites. Top 10 indications for clinical trials in Russia include lung cancer, breast cancer, bronchial asthma, diabetes mellitus, rheumatoid arthritis, ulcerative colitis, infections, lymphoma, multiple sclerosis, and flu. The monthly web-site activity was approximately 13,000 page views with 5,000 individual visitors including over 20% visitors aged 45 year and older (6.00.3 minutes per visit). The platform was presented at several industry conferences and received positive feedback from representatives of clinical trial community. We conducted several focus groups to evaluate the usability of ClinLine.ru. Clinical research field is always developing, trying to implement new, cutting edge technological solutions into all CRO processes. It’s not surprising that almost 94% of Sponsors from our focus group are eager to use ClinLine as another way of communicating with patients and Investigators. 64% of Investigators are willing to use ClinLine for enrollment purposes and 86% have no major qualms with sharing their CV and profile information with interested Sponsors and CRO. Based on the results and feed-back from users, we continue to develop the functionality of the platform
Conclusion
Having a common platform for clinical trial participants will encourage more patients in drug development process, allow better access to clinical trials, streamline communication between patients and investigators, and provide the society with more transparency and understanding of drug research. Feasibility and pre-screening capabilities will improve the site selection process and minimize enrollment timelines. The platform also aims to attract more Sponsors to the Russian clinical trial market. Further steps will include promotion among patient communities including internet and conferences, involvement of more investigators and development of functionality for Sponsors/CRO (i.e. site selection, analytics, etc.)
